Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B
GSK Emerges As A Contender As Others Struggle
Executive Summary
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.
You may also be interested in...
Stockwatch: Bluebird, Arrowhead And Short Memories
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge
Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.
Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?